Dingfu Biotarget Co., Ltd.

Jiangsu Alphamab Biopharmaceuticals Co., Ltd.

Suzhou Alphamab Co., Ltd.

Xitian Zhang

Xin Zhang

Zhang, Xitian

Zhang, Xin

Xiaoxiao Wang

Ting Xu

Jianjian Peng

Yan Luan

Meng Zhao

Hui Ma

Shilong Fu

Xiaolong Pan

Shuli Ma

Yuhao Jin

Shanshan Ning

Qian Li

Tao Xu

Pilin Wang

Kangping Guo

Dong Yang

Qingqing Zhang

Li Han

Jie Li

Huimin Zhang

Haiyan Wu

Li Gao

Qian Chu

Minjie Pang

Yu Bai

Yeqiong Fei

Ling Wang

Kai Fu

Aiwu Zhou

Jie Wu

Hongqin Hu

Xinglu Sun

Ying Fan

Yan Zeng

Disclosed are a method for treating a tumor using a CTLA4-binding protein and a use thereof, wherein the CTLA4-binding protein specifically binds to CTLA4 and does not compete with a ligand of CTLA4 for binding to CTLA4. The CTLA4-binding protein described in the present application can effectively inhibit tumor growth.

Method for treating tumor using anti-CTLA4 single-domain antibodies

The present disclosure provides a dimer formed by two polypeptide chains, with each of the two polypeptide chains comprising an antibody Fc subunit, wherein the dimer comprises two or more immunoglobulin single variable domains (ISVDs), at least one of the ISVDs is specific for PD-L1, and at least one of the ISVDs is specific for CTLA4.

Dimers and use thereof

The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against CTLA4. In particular, the present invention discloses a CTLA4 binding protein and the use thereof, especially the use for treating and/or preventing CTLA4 relevant diseases such as tumor.

Single domain antibody and derivative proteins thereof against CTLA4

Provided are proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.

Proteinaceous heterodimer and use thereof

The present application provides a bispecific antibody or an antibody mixture with common light chains and a preparation method therefor. the present application also provides a nucleic acid molecule encoding the antibody or the mixture, a recombinant vector and a recombinant cell comprising the nucleic acid molecule, as well as a detection and quantitation method for the antibody or the mixture.

Bispecific antibody or antibody mixture with common light chains

The present invention relates to the field of medical biology, and discloses a high-resolution crystal structure of a complex of PD-L1-blocking heavy-chain single-domain antibody KN035 binding with PD-L1, and the use of the crystal structure. The invention also relates to novel PD-L1 binding polypeptides or compounds developed based on the crystal structure and uses thereof.

PD-L1 binding polypeptide or composite

The present disclosure provides proteinaceous complexes, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous complexes, methods for producing the proteinaceous complexes, and uses thereof.

IL-10 EGFR antibody fusion protein and uses thereof

Disclosed are a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof. a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof.

Fully human antibody against human CD 137

The present application provides an anti-OX40 human antibody. In particular, a human antibody specifically binding to OX40 is obtained with yeast display screening, and the affinity of the antibody is improved with affinity maturation. The present application also provides a use of the antibody for the prevention or treatment of tumors.

Anti-OX40 antibody and application thereof

The present disclosure provides proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.

The invention relates to a method for preparing a homodimer protein mixture by using repulsive interaction of charges. The method comprises the step of replacing part of residues with the opposite-charged residues, so that different proteins or antibodies are unfavorable to forming heterodimers due to the repulsive interaction between like charges, while same proteins or antibodies are favorable to forming homodimers due to attractive interaction between opposite charges. The homodimer protein mixture obtained according to the method of the invention can simultaneously act on different epitopes of the same target, and simultaneously inhibit the effects of a plurality of antigens by binding to the antigens from different sources, thereby providing a new approach towards immunological diagnosis and treatment of tumors and other diseases.

Method for preparing homodimer protein mixture by using charge repulsion effect

Growing community of inventors

Jiangsu, China

Xiaoxiao Wang